Ksenchyn O. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Quite often there is a combined course of GERD and arterial hypertension at the same time, as many risk factors are common to these two diseases. The purpose of the study was to study the peculiarities of multichannel impedance-pH monitoring in patients with combined GERD and hypertension and differences in these rates from those in patients with isolated GERD and patients with GERD and concomitant diseases of the digestive system. Object and methods. The study included 79 patients with GERD which were divided into 3 groups: patients with isolated GERD, patients with combined course of GERD and hypertension and patients with GERD and comorbid gastrointestinal disorders. A multichannel impedance-pH monitoring of the esophagus was performed for all patients, namely a 3-hour version with a unified provocative breakfast. Results and discussion. Analysis of values of pH-grams did not reveal a plausible difference (p> 0.05) between groups. When comparing the results of multichannel impedance-pH monitoring, a significantly lower number of acid refluxes in the GERD and hypertension group was found, and significantly higher number of acid refluxes in the group with GERD and comorbid gastrointestinal disorders, and this difference was precisely at the expense of liquid acid reflux. Conclusions. According to the results of multichannel impedance-pH-monitoring, the group of patients differed only in the number of acid refluxes. A decrease in the proportion of acid reflux, in the group with GERD and concomitant hypertension, was detected in comparison with the group of patients with isolated GERD. There is also an increase in the proportion of acid reflux in the group of patients with GERD and concomitant gastrointestinal disorders

gastroesophageal reflux disease, arterial hypertension, diseases of the digestive system, multichannel impedance-pH monitoring.

1. Abrahamovych OO, Faiura OP, Abrahamovych UO. Komorbidnist: suchasnyi pohliad na problemu, klacyfikatsiia. Lvivskyi klinichnyi visnyk. 2015;4(12):56-62. [in Ukrainian].
2. Babak OYa. Osobennosti terapii kislotozavisimykh zabolevaniy pri komorbidnoy patologii: voprosy i otvety. Suchasna gastroenterologіya. 2013;4(72):7-11. [in Russian].
3. Vertkin AL. Komorbidnost: chast 2. Lechashchiy vrach. 2013;8:78-82. [in Russian].
4. Porovskiy YaV, Tetenev FF. Komorbidnost vo vrachebnoy praktike. Sibirskoe meditsinskoe obozrenie. 2015;4:5-10. [in Russian].
5. Moraes-Filho JP, Navarro-Rodriguez T, Eisig JN, Barbuti RC, Chinzon D, Quigley EM. Comorbidities are frequent in patients with gastroesophageal reflux disease in a tertiary health care hospital. Clinics (Sao Paulo). 2009;64(8):785-90.
6. Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30(2):1-9.
7. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. DOI: 10.1016/s0140-6736(05)70151-3
8.  Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. The clinical features and predisposing factors of asymptomatic erosive esophagitis. Digestive Diseases and Sciences. 2016;61(12):3522-9. DOI: 10.1007/s10620-016-4341-9
9. Lu CL. Silent gastroesophageal reflux disease. Journal of Neurogastroenterology and Motility. 2012;18(3):236-8. DOI: 10.5056/ jnm.2012.18.3.236
10.  Wu L, He Y, Jiang B, Sun D, Wang J, Liu M, et al. Trends in prevalence, awareness, treatment and control of hypertension during 2001-2010 in an urban elderly population of China. PLoS One. 2015 Aug 4;10(8):e0132814. DOI: 10.1371/journal.pone.0132814. eCollection 2015.
11. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet. 2011;377(9765):568-77. DOI: 10.1016/S0140-6736(10)62036-3
12. Gudlaugsdottir S, Verschuren WMM, Dees J, Stijnen T, Wilson JHP. Hypertension is frequently present in patients with reflux esophagitis or Barrett’s esophagus but not in those with non-ulcer dyspepsia. European Journal of Internal Medicine. 2002;13(6):369-75. DOI: 10.1016/ S0953-6205(02)00090-0
13. Lee SP, Lee KN, Lee OY, Lee HL, Choi HS, Yoon BC, et al. The relationship between existence of typical symptoms and psychological factors in patients with erosive esophagitis. Journal of Neurogastroenterology and Motility. 2012;18(3):284-90. DOI: 10.5056/jnm.2012.18.3.284
14. Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351- 62. DOI: 10.1136/gutjnl-2017-314722
15. Gridnev AYe. Osobennosti sutochnoy pH-metrii pishchevoda pri sochetanii gastroezofagealnoy reflyuksnoy i gipertonicheskoy bolezni. Suchasna gastroenterologіya. 2015;5(85):7-13. [in Russian].
16.  Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. Montreal definition and classification of gastroesophageal reflux disease: a global evidence–based consensus. Am J Gastroenterol. 2006;101:1900-20.
17. Sirenko YuM, pereklad. Klinichni rekomendatsii z arterialnoi hipertenzii Yevropeiskoho tovarystva hipertenzii (ESH) ta Yevropeiskoho tovarystva kardiolohiv (ESC) 2013 roku. Arteryalnaia hypertenzyia. 2013;4(30):61-157. [in Ukrainian].
18. Chernobrovyi VM, Melashchenko SH, Ksenchyn OO. Diahnostychni mozhlyvosti 200-khvylynnoho postprandialnoho multykanalnoho intraliuminalnoho impedans-рН-monitorynhu stravokhodu porivniano z dobovym variantom. Hastroenterolohiia. 2015;2(56):5-11. [in Ukrainian].
19. Gharib A, Forootan M, Sharifzadeh M, Abdi S, Darvishi M, Eghbali A. Diagnostic Efficacy of 24-hr Esophageal pH Monitoring in Patients with Refractory Gastroesophageal Reflux Disease. Open Access Maced J Med Sci. 2018 Jul 9;6(7):1235-8. DOI: 10.3889/oamjms.2018.268. eCollection 2018 Jul 20.
20. Smolka AJ, Schubert ML. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Curr Top Microbiol Immunol. 2017;400:227-52. DOI: 10.1007/978-3-319-50520-6_10

«Bulletin of problems biology and medicine» Issue 2 Part 2 (151), 2019 year, 127-131 pages, index UDK 616.329/33-002+616.12-008.331

10.29254/2077-4214-2019-2-2-151-127-131